Xiaolei(shirley) Qiu
About Xiaolei(shirley) Qiu
Xiaolei (Shirley) Qiu is a Director at Alamar Biosciences, Inc., with extensive experience in cell biology and molecular biology techniques. She has held various scientific roles at Siemens Healthineers and has a strong academic background, holding a Ph.D. from the University of Florida.
Work at Alamar Biosciences
Xiaolei Qiu currently serves as the Director at Alamar Biosciences, Inc. since 2021. In this role, she leads initiatives focused on the development of high-sensitivity, high-plex immunoassays aimed at early disease detection. Prior to her directorial position, she was the Associate Director at the same company from 2020 to 2021. Her work at Alamar Biosciences emphasizes the facilitation of personalized medication through scientific research and development.
Previous Experience in Research and Industry
Xiaolei Qiu has a diverse background in research and industry. She worked at Siemens Healthineers in various roles, including Senior Scientist from 2012 to 2014, Staff Scientist from 2015 to 2017, and Sr. Manager from 2019 to 2020, all based in Berkeley, California. Additionally, she served as a Scientist at Advanced Cell Diagnostics from 2011 to 2012. Her early career included a postdoctoral fellowship at UC Berkeley from 2009 to 2011.
Education and Expertise
Xiaolei Qiu holds a Doctor of Philosophy (Ph.D.) from the University of Florida, where she gained extensive knowledge in cell biology. She also earned a Bachelor of Science in Biological Science and Technology from Tsinghua University. Her expertise encompasses a wide range of molecular biology techniques, including next-generation sequencing (NGS), quantitative PCR (qPCR), and fluorescence microscopy. She is skilled in animal work, particularly in metabolic profiling and various injection techniques.
Research Focus and Goals
Xiaolei Qiu aims to facilitate personalized medication through her scientific endeavors. Her research focuses on the isolation of stem and progenitor cell subgroups, as well as mammalian cell cultures. She leads projects that develop innovative immunoassays for early disease detection, contributing to advancements in personalized medicine and healthcare.